Adamax Peptide · Research brief

Semax vs Selank vs Adamax: Nootropic Peptides Compared

Real Peptides Research TeamEditorial

Updated September 21, 20269 min read

44 WORDS

Short answer

The most common mistake in a semax vs selank vs adamax comparison isn't picking the wrong compound. It's assuming all three rest on the same published record. Semax and Selank each carry decades of preclinical and clinical literature; Adamax, a structural derivative, does not.

Key takeaways

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) and Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) share a C-terminal Pro-Gly-Pro tail for protease resistance but derive from completely different parent molecules, ACTH(4-10) and tuftsin.
Adamax is a structural modification within the Semax family, and its peer-reviewed record is far thinner than that of either parent compound.
Dihexa, Noopept, Cerebrolysin, NAD+, oxytocin, DSIP and Pinealon each belong to a different molecular class, so most three-way comparisons are cross-category rather than like-for-like.
None of these compounds is an FDA-approved drug, and all are supplied strictly for laboratory research rather than human or veterinary use.
Lyophilised peptides are typically stored at -20°C and held at 2–8°C after reconstitution, with light protection and minimal freeze-thaw cycling.
A usable certificate of analysis shows HPLC purity, mass-spectrometry identity confirmation, and a batch number matching the vial label.

We supply all three to research groups, and the question we get asked most isn't about potency. It's about what the literature can actually support.

Semax vs Selank vs Adamax: what is the difference?

Semax is a heptapeptide analogue of the ACTH(4-10) fragment studied for neurotrophic and attention-related effects. Selank is a heptapeptide analogue of tuftsin studied for anxiolytic-type behaviour. Adamax is an adamantane-modified compound in the Semax family with a far thinner peer-reviewed record. All three are research-use-only compounds, not approved drugs.

Most comparison content treats these three as different strengths of the same product. They aren't. Semax and Selank descend from completely unrelated parent molecules, and Adamax is a chemical modification rather than a separate discovery. What follows covers the sequences and reported mechanisms, how these peptides sit against Dihexa, Noopept, Cerebrolysin, NAD+, oxytocin, DSIP and Pinealon, and what belongs on a certificate of analysis before any of them enters a study.

Three peptides, two parent molecules, one shared design trick

Semax and Selank are both heptapeptides, both developed in Russian neuropeptide research programmes, and both built the same way: take a short fragment of a naturally occurring signalling molecule, then attach a Pro-Gly-Pro tripeptide to the C-terminus so that plasma and tissue peptidases degrade it more slowly.

Semax is Met-Glu-His-Phe-Pro-Gly-Pro, a synthetic analogue of the adrenocorticotropic hormone fragment ACTH(4-10) with the hormonal (corticotropic) activity removed. Published preclinical work associates it with altered expression of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in hippocampal tissue.

Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, an analogue of tuftsin, an immunomodulatory tetrapeptide derived from the heavy chain of IgG. Its literature clusters around anxiolytic-type behaviour in rodent models, GABAergic and monoaminergic signalling, and inhibition of enkephalin degradation.

Adamax is where honesty matters more than marketing. It is described as an adamantane-modified compound in the Semax family, the bulky adamantyl group intended to raise lipophilicity and membrane permeability. Peer-reviewed data on Adamax specifically remains sparse next to the Semax and Selank record.

Here is the detail most comparisons skip: that shared Pro-Gly-Pro tail is an address label, not the message. It governs how long the molecule survives, not what it does. In our experience fielding sequencing and stability questions from research buyers, that single distinction resolves most of the confusion.

Where they sit against Dihexa, Noopept, Cerebrolysin and NAD+

Semax and Selank are short synthetic regulatory peptides, and most compounds they get compared against are not the same class of molecule at all. That is the real answer to almost every three-way query in this space.

A semax vs selank vs dihexa comparison crosses classes: Dihexa is an angiotensin IV analogue reported in preclinical literature to potentiate hepatocyte growth factor signalling at the c-Met receptor, a growth-factor pathway rather than a neuropeptide-regulatory one. Noopept is a proline-containing dipeptide ester (N-phenylacetyl-L-prolylglycine ethyl ester) studied largely in Russian pharmacology, orally active where Semax formulations are typically intranasal or parenteral in published protocols.

Cerebrolysin is not a single molecule at all. It is a porcine brain-derived peptide preparation administered parenterally, trialled in stroke and dementia populations with mixed and contested outcomes, so comparing it to a defined heptapeptide compares a mixture to a sequence. A semax vs selank vs nad+ query crosses an even wider gap: NAD+ is a coenzyme central to mitochondrial redox reactions and sirtuin and PARP enzyme activity, not a peptide.

Oxytocin is a nonapeptide hormone with a defined receptor and a literature centred on affiliative and social behaviour. DSIP (delta sleep-inducing peptide) is a nonapeptide studied for sleep architecture, not cognition. Pinealon, an Ala-Glu-Asp-Gly tetrapeptide from the Khavinson short-peptide work, is studied for interactions with DNA regulatory regions.

What belongs on the paperwork before any of these enters a study

The compound is only as good as its certificate, and the three most useful lines on it are HPLC purity, mass-spectrometry identity confirmation, and a batch number that matches the label on the vial in your hand. Anyone running a semax vs selank vs adamax comparison in the lab should confirm all three across every vial in the set, because an identity mismatch between arms destroys the comparison before the first data point.

Handling is the second failure point. Lyophilised peptides are typically held at -20°C; once reconstituted, they belong at 2–8°C, protected from light, with a working shelf life far shorter than the powder. Repeated freeze-thaw cycles and ambient excursions degrade peptide bonds in ways no visual inspection catches. Amidated variants exist precisely because C-terminal amidation can improve stability against carboxypeptidases, which is why formats differ across a catalogue.

Our team documents every batch this way, and researchers comparing formats can review Semax liquid spray, Selank liquid spray, Adamax peptide, Dihexa, Cerebrolysin, Pinealon, oxytocin and NAD+ alongside the published certificates of analysis and the wider research catalogue.

These compounds are supplied for laboratory research only, not for human or veterinary use. If your question concerns an animal's health, talk to your veterinarian rather than sourcing a research compound.

Semax vs Selank vs Adamax: Side-by-Side Research Comparison

This table maps each compound by molecular class, what the published literature actually focuses on, and how deep that record runs. Depth of evidence, not perceived strength, is the column that should drive procurement decisions.

Compound	Molecular class	Reported focus in the literature	Depth of published record	Bottom line for research use
Semax	Heptapeptide, ACTH(4-10) analogue with Pro-Gly-Pro tail	Neurotrophic factor expression (BDNF, NGF), attention and ischaemia models	Extensive Russian preclinical and clinical literature, limited Western replication	The best-documented compound of the three and the sensible reference arm in any comparison
Selank	Heptapeptide, tuftsin analogue with Pro-Gly-Pro tail	Anxiolytic-type behaviour, GABAergic and monoaminergic signalling, enkephalin degradation	Substantial Russian record, thinner than Semax, minimal independent replication	Studied for a different endpoint entirely; not a stronger or weaker Semax
Adamax	Adamantane-modified compound in the Semax family	Increased lipophilicity and membrane permeability, described mostly in supplier and preliminary sources	Sparse peer-reviewed data specific to the molecule	Use as an exploratory arm, never as a substitute for a compound with a real literature base
Dihexa	Angiotensin IV analogue, oligopeptide	Hepatocyte growth factor and c-Met receptor signalling, synaptogenesis models	Preclinical only, no meaningful human data	Different pathway class entirely; comparing it to Semax compares growth factor signalling to neuropeptide regulation
Noopept	Proline-containing dipeptide ester	Cognitive and neuroprotective endpoints in rodent and Russian clinical work	Moderate, concentrated in one research tradition	The closest small-molecule cousin, orally active, and the easiest compound to confuse with a peptide
Cerebrolysin	Porcine brain-derived peptide mixture	Neurotrophic effects in stroke and dementia trials	Large trial programme with genuinely mixed and debated results	A mixture, not a sequence; batch-to-batch definition is a structural limitation of the comparison
NAD+	Coenzyme, not a peptide	Mitochondrial redox balance, sirtuin and PARP enzyme activity	Broad metabolic literature, separate field	Not a competing nootropic peptide; the comparison only makes sense as a metabolic versus signalling study
Oxytocin	Nonapeptide hormone	Affiliative and social behaviour, receptor-specific central effects	Large, mature literature across species	An endogenous hormone with defined receptor pharmacology, not an engineered analogue
DSIP	Nonapeptide (delta sleep-inducing peptide)	Sleep architecture and stress response models	Older, inconsistent, largely unreplicated	Belongs to sleep research; pairing it with Semax or Selank compares different outcome domains
Pinealon	Ala-Glu-Asp-Gly tetrapeptide	Interactions with DNA regulatory regions, cell protection models	Narrow, concentrated in the Khavinson short-peptide programme	A gene-regulation hypothesis rather than a receptor-signalling one

What If: Nootropic Peptide Research Scenarios

What if the Adamax vial looks different from the Semax vial?

Document the difference, photograph it, and check the batch record before reconstituting anything. Lyophilised cake appearance varies legitimately with fill volume, lyophilisation cycle and excipient content, so a flatter or more fragmented cake is not automatic evidence of a problem. What is a problem: discolouration, visible moisture, or a cake that has collapsed into a residue, all of which point to a temperature excursion or seal failure in transit.

What if a shipment of lyophilised peptide arrives warm?

Quarantine the vials and contact the supplier before opening them. Lyophilised powder tolerates short ambient exposure far better than reconstituted solution, which is why peptides ship dry, but tolerance is not immunity and prolonged heat can degrade peptide bonds without any visible change. Neither appearance nor a home potency guess can detect partial degradation, so the only defensible move is to treat the batch as unverified.

What if a supplier cannot produce a certificate of analysis?

Treat the absence of a certificate as the answer to your question. Without HPLC purity and mass-spectrometry identity data tied to a specific batch, there is no way to confirm that the vial contains the sequence on the label, let alone at the stated quantity. This matters most in multi-arm comparisons, where an unverified arm silently contaminates every conclusion drawn from the study.

The Unglamorous Truth About Ranking Nootropic Peptides

Let's be direct about this: ranking semax vs selank vs adamax by strength is a category error, and anyone offering you a clean hierarchy is selling something. Semax and Selank were designed for different endpoints, tested in different models, and reported against different behavioural measures. Adamax has no comparable literature to rank with. Beyond that, most of the Semax and Selank record comes from a single national research tradition with limited independent Western replication, which is a real evidentiary weakness rather than a footnote. The honest position is that these are interesting research compounds with uneven evidence, not graded tiers of the same effect.

The semax vs selank vs adamax comparison tends to get asked as a shopping question when it is really a study-design question. Once you accept that one compound descends from a pituitary hormone fragment, one from an immunoglobulin fragment, and one from a chemist's attempt to make the first more lipophilic, the idea of a single winner stops making sense. What you choose depends on the pathway you are interrogating and how much published groundwork you need under it. Pick the arm with the deepest record as your reference, and treat everything thinner than that as exploratory.

References

Peer-reviewed sources on Selank indexed in PubMed, listed for research context. Real Peptides supplies Selank for laboratory research use only.

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of experimental biology and medicine, 2022. PMID 36322304. doi:10.1007/s10517-022-05624-x
The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress. Current reviews in clinical and experimental pharmacology, 2021. PMID 32621722. doi:10.2174/1574884715666200704152810
Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank. Bulletin of experimental biology and medicine, 2020. PMID 32651826. doi:10.1007/s10517-020-04868-9
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of experimental biology and medicine, 2019. PMID 31625062. doi:10.1007/s10517-019-04588-9
Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress. Bulletin of experimental biology and medicine, 2019. PMID 31243679. doi:10.1007/s10517-019-04512-1
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and peptide letters, 2018. PMID 30255741. doi:10.2174/0929866525666180925144642
Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress. Bulletin of experimental biology and medicine, 2017. PMID 28853100. doi:10.1007/s10517-017-3817-8

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Semax is a heptapeptide analogue of the ACTH(4-10) fragment, with the corticotropic hormonal activity removed, and its literature centres on neurotrophic factor expression such as BDNF and NGF. Selank is a heptapeptide analogue of tuftsin, an immunomodulatory fragment of IgG, and its literature centres on anxiolytic-type behaviour and GABAergic signalling. They share only the C-terminal Pro-Gly-Pro tail that slows enzymatic degradation, not a mechanism.

Semax has the deepest published record of the three, with extensive preclinical and clinical literature from Russian research programmes. Selank follows with a substantial but thinner record focused on anxiolytic endpoints. Adamax, described as an adamantane-modified compound in the Semax family, has sparse peer-reviewed data specific to the molecule, which is why it functions better as an exploratory arm than a reference compound.

These compounds are sold as research-use-only materials for laboratories and research groups, not as drugs or supplements. They are not FDA-approved and are never supplied for human or veterinary consumption. Buyers are responsible for confirming that their intended laboratory use complies with the regulations that apply to them.

Pricing varies widely by compound, quantity, purity specification and format, so current per-vial pricing is best checked directly on the product pages. Liquid spray formats and lyophilised powder are typically priced differently because of fill volume and stability requirements. What should never vary is the paperwork: a certificate of analysis with HPLC purity and mass-spectrometry identity confirmation should accompany the batch regardless of price.

Lyophilised peptide powder is typically held at -20°C and protected from light and moisture. Once reconstituted, solutions are generally refrigerated at 2–8°C and have a much shorter working life than the dry powder. Repeated freeze-thaw cycling and ambient temperature excursions can degrade peptide bonds without producing any visible change in the vial.

Noopept is a proline-containing dipeptide ester, N-phenylacetyl-L-prolylglycine ethyl ester, rather than a peptide analogue built from a hormone or immunopeptide fragment. It is orally active, which distinguishes it from Semax and Selank, whose published protocols are typically intranasal or parenteral. The comparison is cross-category: a small-molecule dipeptide ester against two engineered regulatory peptides.

Not directly, because Cerebrolysin is not a single defined molecule. It is a porcine brain-derived peptide preparation containing a mixture of low-molecular-weight fragments, administered parenterally and trialled in stroke and dementia populations with mixed and debated results. Comparing it to Semax compares a biologically derived mixture to a synthetic seven-amino-acid sequence, which limits how much a head-to-head study can conclude.

Mostly because of search behaviour rather than chemistry. NAD+ is a coenzyme central to mitochondrial redox reactions and to sirtuin and PARP enzyme activity, not a peptide at all. A study pairing NAD+ with Semax or Selank is comparing a metabolic cofactor to receptor-level signalling compounds, which can be a legitimate design but is not a like-for-like comparison.

The main laboratory risks are contamination of the vial during reconstitution, degradation from temperature excursions or freeze-thaw cycling, and identity error when multiple similar-looking vials are handled together. Sterile technique, single-use needles for drawing, and clear batch labelling address most of it. Any compound without a batch-matched certificate of analysis should be treated as unverified material rather than a usable research input.

Semax amidate carries a C-terminal amide group in place of the free carboxyl terminus. Amidation can improve resistance to carboxypeptidase degradation, which is why amidated variants exist as a separate format in research catalogues. The core sequence is the same, so the difference is stability and handling behaviour rather than a different parent molecule.

Both are short peptides studied in adjacent Russian and Eastern European research traditions, which is why they cluster in the same searches. DSIP, a nonapeptide studied for sleep architecture, addresses a different outcome domain entirely. Pinealon, an Ala-Glu-Asp-Gly tetrapeptide from the Khavinson short-peptide programme, is studied for interactions with DNA regulatory regions rather than receptor signalling.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA